Skip to NavigationSkip to content

Lixiana

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana

Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial fibrillation patients undergoing catheter ablation.

The study showed the uninterrupted anticoagulation regimen with 60mg edoxaban versus uninterrupted vitamin K antagonists, in patients undergoing catheter ablation resulted in low event rates for both thromboembolic and bleeding events.

Daiichi scores another NICE nod for Lixiana

Daiichi Sankyo

NICE has recommended in draft guidance the anti-blood clotting drug Daiichi Sankyo’s Lixiana for preventing stroke and blood clots in adults with atrial fibrillation.

The draft guidance gives doctors the go-ahead to prescribe Lixiana (edoxaban) to prevent strokes and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, including congestive heart failure, hypertension, diabetes, a prior stroke or transient ischaemic attack (mini-stroke), or who are aged 75 years or older.

NICE recommends Daiichi’s Lixiana for blood clots

Daiichi Sankyo
Daiichi has earned NICE approval for its newly-launched drug Lixiana

Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug Lixiana as a treatment for clots in the legs and lungs.

The NICE decision comes just days after Daiichi launched Lixiana (edoxaban) in the UK, and shortly after the Japanese firm earned European approval for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults and the prevention of stroke and clots in adults with

Daiichi Sankyo launches clotting drug Lixiana in UK

Daiichi image
Daiichi Sankyo's Lixiana is the fourth new anticoagulant to hit the UK market

Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.

Lixiana (edoxaban) reduces the risk of blood clots in people with atrial fibrillation, which is thought to be the commonest heart rhythm disorder.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches